Champions Oncology (CSBR) EPS (Basic) (2016 - 2026)
Champions Oncology has reported EPS (Basic) over the past 17 years, most recently at -$0.02 for Q1 2026.
- For Q1 2026, EPS (Basic) fell 106.06% year-over-year to -$0.02; the TTM value through Jan 2026 reached -$0.17, down 136.17%, while the annual FY2025 figure was $0.34, 162.96% up from the prior year.
- EPS (Basic) for Q1 2026 was -$0.02 at Champions Oncology, down from $0.02 in the prior quarter.
- Over five years, EPS (Basic) peaked at $0.33 in Q1 2025 and troughed at -$0.19 in Q2 2023.
- A 5-year average of -$0.03 and a median of -$0.02 in 2022 define the central range for EPS (Basic).
- Biggest five-year swings in EPS (Basic): plummeted 12583.1% in 2023 and later skyrocketed 273.68% in 2025.
- Year by year, EPS (Basic) stood at -$0.0 in 2022, then plummeted by 12583.1% to -$0.15 in 2023, then soared by 133.33% to $0.05 in 2024, then tumbled by 60.0% to $0.02 in 2025, then crashed by 200.0% to -$0.02 in 2026.
- Business Quant data shows EPS (Basic) for CSBR at -$0.02 in Q1 2026, $0.02 in Q4 2025, and -$0.03 in Q3 2025.